Compare STVN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STVN | GRFS |
|---|---|---|
| Founded | 1949 | 1940 |
| Country | Italy | Spain |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.2B |
| IPO Year | 2021 | 2008 |
| Metric | STVN | GRFS |
|---|---|---|
| Price | $14.72 | $8.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $24.84 | $10.37 |
| AVG Volume (30 Days) | 361.4K | ★ 585.5K |
| Earning Date | 11-03-2026 | 07-28-2022 |
| Dividend Yield | 0.31% | ★ 1.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.91 | $2.02 |
| Revenue Next Year | $8.95 | $6.02 |
| P/E Ratio | $27.15 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.89 | $6.96 |
| 52 Week High | $27.00 | $9.77 |
| Indicator | STVN | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 21.78 | 74.93 |
| Support Level | $13.80 | $7.52 |
| Resistance Level | $17.19 | $8.83 |
| Average True Range (ATR) | 0.86 | 0.19 |
| MACD | -0.23 | 0.11 |
| Stochastic Oscillator | 16.54 | 95.87 |
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.